Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21076643 | 0.84 | TRPV4 (0.37) | CHRNA7TRPV4 | |
| SCHEMBL19619488 | 0.83 | TRPV4 (0.39) | CHRNA7TRPV4 | |
| SCHEMBL1694606 | 0.80 | CHRNA7 (0.38) | CHRNA7TRPV4 | |
| SCHEMBL18570673 | 0.79 | TRPV4 (0.39) | CHRNA7TRPV4 | |
| SCHEMBL8253665 | 0.77 | PDE4A (0.39) | CHRNA7 | |
| SCHEMBL20857362 | 0.77 | CHRNA7 (0.36) | CHRNA7 | |
| SCHEMBL21675886 | 0.77 | CHRNA7 (0.39) | CHRNA7 | |
| SCHEMBL17775982 | 0.77 | TRPV4 (0.36) | CHRNA7TRPV4 | |
| SCHEMBL17775927 | 0.77 | TRPV4 (0.36) | CHRNA7TRPV4 | |
| SCHEMBL2609310 | 0.75 | TRPV4 (0.52) | CHRNA7TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | CHRNA7 169/4885TRPV4 1472/4885 |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | CHRNA7 169/4885TRPV4 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.